|
Lipid-Based Drug Delivery Systems Focus Group |
 |
Purpose and Description
There is growing interest and investment in the use of lipid-based systems in drug
discovery and product development to effectively overcome physical and biological
barriers related to poor aqueous solubility and stability, membrane permeability,
drug efflux and bioavailability. The rapid growth in this area is primarily due
to the diversity and versatility of pharmaceutical grade lipid excipients and drug
formulations and their compatibility with liquid, semi-solid and solid dosage forms.
An array of lipid systems is available to pharmaceutical formulators such as, emulsions,
micellar solutions, liposomes, lipid nanoparticles, self-emulsifying lipid formulations,
solid dispersions, dry emulsions, solid-liquid compacts and drug-lipid conjugates.
This along with ongoing advances in manufacturing technologies has resulted in the
rapid introduction of lipid-based drug formulations into the marketplace with a
number of drug products on the market and several in clinical development. Parenteral
formulations on the market include emulsions, micellar solutions and liposomes.
In the case of oral administration, the marketed products are primarily in the form
of oral lipid solutions with and without co-solvents and/or filled into hard or
soft gelatine capsule. As we better understand the manufacturing and in vivo processing
and site-specific targeting of lipidic formulations and bridge product quality with
in vivo performance, expanded product development use and market can be expected.
It is the mission of the LBDDS FG to continue advancing the science and pharmaceutical
applications of lipid-based systems in a multidisciplinary approach. The specific
areas of involvement include:
- small molecule and macromolecule (peptide/protein, vaccine, and nucleic acid/gene)
delivery
- lipidic prodrugs and self-assembled lipid systems in drug discovery and development
- drug solubilization and site-specific passive and active targeting aspects of lipids
- biopharmaceutical aspects and drug absorption mechanisms
- physicochemical determinants of the utility of lipidic excipients and their impact
on product performance for immediate and sustained drug release
- in vitro and in vivo methodologies for the evaluation of lipid-based formulations
and potential IVIVC
- processing and manufacturing aspects of lipidic formulations
- regulatory considerations of lipid excipients
- emerging lipid-based drug delivery technologies
Any AAPS member with interest in lipid-based systems is welcome to join the focus
group and actively participate in fulfilling its mission and objectives.
AAPS WORKSHOP REPORT
AAPS
Workshop on Effective Utilization of Lipid-Based Systems to Enhance the Delivery
of Poorly Soluble Drugs: Physicochemical, Biopharmaceutical and Product Development
Considerations, March 5-6, 2007 (PDF)
Meeting Minutes
-
Membership Meeting Presentation, November 2008 (PDF)
-
Membership Meeting Presentation, November 2007 (PDF)
-
Membership Meeting Minutes, October 2006 (PDF)
-
Membership Meeting Presentation, October 2006 (PDF)
- Membership
Meeting Minutes, November 8, 2005 (PDF)
- Membership Meeting Agenda,
November 8, 2005 (PDF)
- Business
Meeting Minutes, October 29, 2003 (PDF)
JOIN THE LIPID-BASED DRUG DELIVERY SYSTEMS FOCUS GROUP
To join the Lipid-Based Drug Delivery Systems Focus Group, click here.
Back To Top
|
|
 |
 |
 |
 |
Chair-Elect Anette Mullertz, Ph.D Bioneer:FARMA, Faculty of Pharmaceutical Sciences, University of Copenhagen Copenhagen Ĝ, Denmark |
Steering Committee Member Mei-Ling Chen, Ph.D Office of Pharmaceutical Science, Food and Drug Administration Potomac, MD United States |
Steering Committee Member Asis Jain Roquette America , UNITED STATES |
|
|